Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To define the objective response rate associated with the administration of vorinostat in combination with bortezomib to patients with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens, who meet both of the following conditions: Refractory to Bortezomib (administered either alone or in combination with other agents); defined as no response on prior bortzeomib-containing regimens or progression on or within 60 days of a bortezomib-containing regimen. Relapsed, refractory, intolerant, and/or ineligible (in the opinion of the Investigator) to other therapies, including an IMid (thalidomide OR lenalidomide).
Inclusion criteria
- Multiple myeloma